401 related articles for article (PubMed ID: 31995677)
1. A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia.
Caroff SN; Citrome L; Meyer J; Sajatovic M; Goldberg JF; Jain R; Lundt L; Lindenmayer JP; McEvoy JP; McIntyre RS; Tohen M; Ketter TA
J Clin Psychiatry; 2020 Jan; 81(2):. PubMed ID: 31995677
[TBL] [Abstract][Full Text] [Related]
2. Medication Options and Clinical Strategies for Treating Tardive Dyskinesia.
Citrome LL
J Clin Psychiatry; 2020 Jan; 81(2):. PubMed ID: 31995679
[TBL] [Abstract][Full Text] [Related]
3. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
Caroff SN; Aggarwal S; Yonan C
J Comp Eff Res; 2018 Feb; 7(2):135-148. PubMed ID: 28965423
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management.
Salem H; Pigott T; Zhang XY; Zeni CP; Teixeira AL
Expert Rev Neurother; 2017 Sep; 17(9):883-894. PubMed ID: 28750568
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment.
Correll CU; Kane JM; Citrome LL
J Clin Psychiatry; 2017; 78(8):1136-1147. PubMed ID: 29022654
[TBL] [Abstract][Full Text] [Related]
6. Valbenazine for the treatment of tardive dyskinesia.
Seeberger LC; Hauser RA
Expert Opin Pharmacother; 2017 Aug; 18(12):1279-1287. PubMed ID: 28699794
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
[TBL] [Abstract][Full Text] [Related]
8. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
Seigneurie AS; Sauvanaud F; Limosin F
Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
Niemann N; Jankovic J
Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
[TBL] [Abstract][Full Text] [Related]
11. Tardive Dyskinesia: Treatment Update.
Arya D; Khan T; Margolius AJ; Fernandez HH
Curr Neurol Neurosci Rep; 2019 Aug; 19(9):69. PubMed ID: 31420757
[TBL] [Abstract][Full Text] [Related]
12. Medication appropriateness tool for co-morbid health conditions in dementia: consensus recommendations from a multidisciplinary expert panel.
Page AT; Potter K; Clifford R; McLachlan AJ; Etherton-Beer C
Intern Med J; 2016 Oct; 46(10):1189-1197. PubMed ID: 27527376
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic-induced tardive dyskinesia: update on epidemiology and management.
Widschwendter CG; Hofer A
Curr Opin Psychiatry; 2019 May; 32(3):179-184. PubMed ID: 30720484
[TBL] [Abstract][Full Text] [Related]
14. Deutetrabenazine in the treatment of tardive dyskinesia.
Niemann N; Jimenez-Shahed J
Neurodegener Dis Manag; 2019 Apr; 9(2):59-71. PubMed ID: 30702019
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological treatment of tardive dyskinesia: recent developments.
Caroff SN; Campbell EC; Carroll B
Expert Rev Neurother; 2017 Sep; 17(9):871-881. PubMed ID: 28727483
[TBL] [Abstract][Full Text] [Related]
16. Revisiting Tardive Dyskinesia: Focusing on the Basics of Identification and Treatment.
Citrome L; Saklad SR
J Clin Psychiatry; 2020 Feb; 81(2):. PubMed ID: 32078259
[TBL] [Abstract][Full Text] [Related]
17. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
Sarva H; Henchcliffe C
Expert Rev Clin Pharmacol; 2018 Mar; 11(3):209-217. PubMed ID: 29338466
[TBL] [Abstract][Full Text] [Related]
18. Impact-Tardive Dyskinesia (Impact-TD) Scale: A Clinical Tool to Assess the Impact of Tardive Dyskinesia.
Jackson R; Brams MN; Carlozzi NE; Citrome L; Fritz NE; Hoberg AR; Isaacson SH; Kane JM; Kumar R
J Clin Psychiatry; 2022 Nov; 84(1):. PubMed ID: 36449471
[No Abstract] [Full Text] [Related]
19. Treatment of Tardive Dyskinesia.
Bashir HH; Jankovic J
Neurol Clin; 2020 May; 38(2):379-396. PubMed ID: 32279716
[TBL] [Abstract][Full Text] [Related]
20. Use of Bone Marrow Concentrate to Treat Pain and Musculoskeletal Disorders: An Academic Delphi Investigation.
Centeno CJ; Jerome MA; Pastoriza SM; Shapiro S; Mautner K; Malanga GA; DePalma MJ; Mason RA; Stemper I; Dodson E
Pain Physician; 2021 May; 24(3):263-273. PubMed ID: 33988946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
